Barth syndrome, a rare x-linked defect in the Tafazzin (TAZ) enzyme involved in cardiolipin remodeling, has been targeted by Elamipretide in the TAZPOWER trial. This evidence concerns the gene TAFAZZIN and Barth syndrome.